With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA.
INTRODUCTION
Systemic juvenile idiopathic arthritis (sJIA) affects between 5% and 15% of all children with JIA in North America and Europe [1] . In Asia, however (including India and Japan), this form of the disease may account for up to 50% of all JIA cases [2, 3] . Despite being relatively rare, sJIA is responsible for nearly two thirds of all childhood arthritis mortality [4] [5] [6] . Although sJIA is equally distributed among girls and boys and can occur at any age, it often affects younger children [7, 8] .
The diagnosis of sJIA is a diagnosis of exclusion requiring a thorough work-up of infectious diseases and malignancies, especially in those patients in whom arthritis is absent at onset. Diagnostic criteria include a history of arthritis in any number of joints and at least 2 weeks of daily monophasic or biphasic fevers accompanied by at least one of the following:
• evanescent, salmon-pink-colored rash on the trunk or overlying the joints;
• hepatosplenomegaly;
• generalized lymphadenopathy;
• serositis (pericarditis, pleuritis).
It is well known that arthritis may be absent at disease onset, which often leads to delays A. Reiff [9] .
Macrophage activation syndrome (MAS), especially during the active systemic phase of the disease, represents the most serious complication and is associated with a high mortality rate [10, 11] .
Prior to the introduction of the newer biologic treatments approximately one third of sJIA patients had a monophasic disease course and more than half developed erosive polyarticular arthritis, with potential long-term disability [2, 9, 12] .
Although the etiology of sJIA remains unknown, recent scientific evidence seems to suggest that this subform of JIA has many traits of an autoinflammatory rather than an autoimmune disorder, and leukocyte transcriptional signatures can be used to distinguish sJIA from other febrile illnesses [13] . Pascual et al. analyzed transcriptional patterns of freshly isolated blood mononuclear cells from patients with active sJIA in addition to analyzing transcriptional changes induced upon culturing healthy blood mononuclear cells with serum from active sJIA patients [14] .
The results revealed that sJIA serum upregulated interleukin-1 (IL-1) transcription in healthy cells and that IL-1 protein secretion was induced in a disease-activity-dependent manner. IL-1β-induced genes such as pentraxin 3, potassium inward-rectifier channel, subfamily J, member 15 (KCNJ15), or adenosine triphosphate (ATP)-sensitive inward rectifier potassium channel were found to be upregulated in peripheral blood mononuclear cells in the majority of active sJIA patients. These patterns normalized after treatment with anakinra. Additionally, mononuclear cells from patients with active sJIA were found to secrete excess IL-1β protein upon activation, while interleukin-6 (IL-6) and tumor necrosis factor (TNF) production did not differ significantly from controls, suggesting a specific dysregulation of the IL-1 pathway in patients with sJIA [14] .
As reviewed previously, IL-1 is the key cytokine in autoinflammatory syndromes and an important mediator of sJIA [15, 16] . IL-1β
and IL-1α are formed from pro-IL-1 via caspase activity. While IL-1α is mostly membrane-bound, IL-β is synthesized by monocytes, macrophages, and dendritic cells and plays a pivotal role in the induction of fever and rash and stimulates the level of circulating IL-6 [12] [13] [14] [15] .
In addition, other cytokines such as IL-6, interleukin-7 (IL-7), and interleukin-18 (IL-18) play a more dominant role in this disease than in other forms of JIA. Increased plasma levels of IL-6 and IL-1 result in higher levels of acutephase reactants and myeloid-related proteins (MRP 8 and 14) , increased production and mobilization of platelet and white blood cells, and anemia [15] [16] [17] [18] [19] [20] [21] [22] [23] .
Conversely, IL-6 is a pleiotropic cytokine that regulates immune responses and inflammatory reactions. IL-6, alone or with other cytokines, interacts with various cells such as T cells, B cells, lymphocytes, monocytes, and fibroblasts, driving synovial proliferation, inflammation, autoimmunity, and destruction of articular structures through the activation of osteoclasts [24] . Both membrane-bound interleukin-6 receptor (IL-6R) and the soluble form of IL-6R are able to mediate proinflammatory IL-6 signaling through the interaction with the cytokine receptor subunit glycoprotein gp130 [25] .
Like IL-1, IL-6 is associated with many of the manifestations of sJIA such as fever, rash, lymphadenopathy, hepatosplenomegaly, anemia, and poor growth [21, 22] . Markedly increased IL-6 levels in serum and synovial fluid are one of the hallmark features of sJIA. IL-6 is especially elevated during or just before fever spikes, while it is often only marginally elevated in between fever attacks [18] .
An extensive literature search was conducted using the PubMed and Ovid medical databases. Keywords included search terms such as "juvenile idiopathic arthritis," "systemic," "arthritis," "macrophage activation syndrome," "treatment," "anakinra," "IL-1ra," "rilonacept," and "tocilizumab," and searches for interleukins 1, 6, 15, and 18. A recently published study [32] Six of the eleven nonresponders to anakinra responded to a single dose of canakinumab.
Notably, nonresponders had a substantially higher number of active joints (median, 33.5 joints) and somewhat lower levels of systemic inflammation relative to responders (median, 9 joints) [36] .
Comparable results were seen in the subsequent two phase 3 studies with canakinumab in 84 patients with sJIA [40] . In this study the average age of patients was 8.5 years and the average disease duration was fairly short at 2 years. All patients had fevers and/or rash, but the inclusion criteria required those symptoms to be present only for at least a day.
Even though the average swollen joint count was about 8, the range was fairly high, with some patients having up to 58 swollen joints.
After a month of treatment, ACR pediatric 50 and 100 were achieved by 76% and 32% of the patients compared to only 5% and 2.4% of the patients on placebo. In general, monthly dosing with canakinumab (4 mg/kg/month) significantly reduced the risk of flare and enabled successful steroid tapering/discontinuation while demonstrating an acceptable safety and tolerability profile. Infections, predominantly of the upper respiratory tract, some serious, were the most frequent adverse events reported.
A total of 5 cases of MAS were observed including 4 patients in the canakinumab and one patient in the placebo groups, three of which were considered life-threatening, and two of which resulted in death [40] .
Safety of Anti-IL-1 Treatments
To my knowledge, none of the published anti-IL-1 trials reported treatment-related deaths, malignancies, or opportunistic infections, including tuberculosis. In general infections occur more frequently with anti-IL-1 agents than in placebo-treated patients, and serious infections have been reported but appear to be generally rare.
Treatment with Tocilizumab
Tocilizumab (Actemra ® ; Hoffmann-La Roche
Ltd., Ontario, Canada) is a humanized, monoclonal anti-IL-6 receptor antibody that binds to soluble and membrane-bound IL-6 receptors, specifically blocking IL-6 actions [24] . 
Phase 1
The active systemic phase is characterized by the presence of systemic disease manifestations
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A r t h r i t i s Fig. 1 . Course of systemic juvenile idiopathic arthritis (sJIA). Although part of a continuous spectrum and variable between patients, sJIA seems to follow a certain cytokine predominance that defines the various disease stages. [48] . This phase may precede the development of arthritis by weeks or even, in rare cases, years [9] .
Clinically this phase most closely resembles an autoinflammatory syndrome, and anti-IL-1 therapy appears to be the most effective treatment. Preliminary evidence seems to suggest that anti-IL-1 therapy in this phase might even prevent further disease progression [32] . In the personal opinion of the author, the role of anti-IL-6 therapy in this phase remains unclear, while treatment with anti-TNF agents appears to have little or no effect.
Phase 2
In this overlap phase, arthritis is becoming increasingly prevalent, while systemic symptoms are still present but tend to be less prominent and regular than in phase 1. The literature quotes a progression to aggressive, erosive polyarticular arthritis in up to 80% of sJIA patients [2, 3] . In this phase treatment with anti-IL-1 therapy appears to be less effective than in phase 1. Studies with rilonacept and canakinumab suggest a beneficial response in 50%-60% of the patients (see above). At the same time treatment with anti-TNF agents remains suboptimal. In this phase, treatment with anti-IL-6 agents such as tocilizumab appears to be the best treatment strategy. It is apparent that sJIA requires disease-stagespecific treatment that will ultimately lead to better outcomes and a decrease in mortality.
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